Clinical Trial Update: SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase 2 study SARC018 evaluated mocetinostat in combination with gemcitabine for metastatic leiomyosarcoma; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• Gemzar (gemcitabine)
• Mocetinostat (mocetinostat)

Snippet

Sponsor: Sarcoma Alliance for Research through Collaboration | Conditions: Metastatic Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-29